Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of subcutaneous C1-esterase inhibitor prophylaxis for hereditary angioedema in Japanese patients
2019-003921-99Phase 3
- Sponsor
- CSL Limited
- Start
- Apr 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of c1-esterase inhibitor in hereditary angioedema (HAE), hereditary angioedema type I (HAE-I) and Hereditary Angioedema Type 2 (HAE2), sponsored by CSL Limited. Primary endpoint: Time-normalized number of hereditary angioedema attacks during treatment.
02
Drugs
c1-esterase inhibitor
03
Conditions
hereditary angioedema (HAE)hereditary angioedema type I (HAE-I)Hereditary Angioedema Type 2 (HAE2)
Beyond the preview
Go deeper on 2019-003921-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003921-99.